Literature DB >> 26288383

Correlates to seroprevalent herpes simplex virus type 2 among rural Appalachian drug users.

Dustin B Stephens1,2, April M Young2,3, Ursula L Mullins2, Jennifer R Havens1,2.   

Abstract

Herpes simplex virus type 2 (HSV-2) is the most common cause of genital ulcer disease and, along with substance abuse, an important HIV risk factor. Therefore, the purpose of this study was to examine HSV-2 seroprevalence in a sample of drug users in rural Appalachia. Rural Appalachian individuals age 18 or older reporting non-medical use of prescription opioids, heroin, crack/cocaine, or methamphetamine in the past 6 months (n = 499) were included. Behavioral, demographic, and sexual network data were collected using interviewer-administered questionnaires. Participants' serum was tested for HSV-2 antibodies using the Biokit rapid test (Lexington, MA). The estimated population seroprevalence of HSV-2 was 14.4% (95%CI: 9.6-19.4%). Only 8.8% were aware of being HSV-2+, and unprotected sex was reported in 80% of serodiscordant sexual relationships. In a multivariate model, female gender, age, older age at first oral sex, and frequency of unprotected sex in the sexual network were independently associated with HSV-2 seropositivity. Despite lower seroprevalence than that reported in similar studies of substance abusers, targeted interventions to reduce sexual risk behavior are warranted in this underserved population. Network-informed approaches with particular focus on women, older individuals, and those engaging in frequent unprotected sex are recommended.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  HIV risk; HSV-2; drug use; genital herpes

Mesh:

Substances:

Year:  2015        PMID: 26288383      PMCID: PMC5559617          DOI: 10.1002/jmv.24358

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  40 in total

1.  Racial/ethnic disparities in undiagnosed infection with herpes simplex virus type 2.

Authors:  Enrique R Pouget; Trace S Kershaw; Kim M Blankenship; Jeannette R Ickovics; Linda M Niccolai
Journal:  Sex Transm Dis       Date:  2010-09       Impact factor: 2.830

2.  Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010.

Authors:  Heather Bradley; Lauri E Markowitz; Theda Gibson; Geraldine M McQuillan
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

3.  Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention.

Authors:  W E Lafferty; L Downey; C Celum; A Wald
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

4.  Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-04-23       Impact factor: 17.586

5.  Prevalence of HIV and risky sexual behaviors among rural drug users: does age matter?

Authors:  Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Jennifer R Havens; April Young
Journal:  Ann Epidemiol       Date:  2012-08-14       Impact factor: 3.797

6.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

7.  The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.

Authors:  Kwame Owusu-Edusei; Harrell W Chesson; Thomas L Gift; Guoyu Tao; Reena Mahajan; Marie Cheryl Bañez Ocfemia; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-03       Impact factor: 2.830

Review 8.  Variations in sexual risks in drug users: emerging themes in a behavioral context.

Authors:  David D Celentano; Amanda D Latimore; Shruti H Mehta
Journal:  Curr HIV/AIDS Rep       Date:  2008-11       Impact factor: 5.071

9.  STD-/HIV-related sexual risk behaviors and substance use among U.S. rural adolescents.

Authors:  Alice F Yan; Yu-Wen Chiu; Carolyn A Stoesen; Min Qi Wang
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

10.  Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015.

Authors:  Caitlin Conrad; Heather M Bradley; Dita Broz; Swamy Buddha; Erika L Chapman; Romeo R Galang; Daniel Hillman; John Hon; Karen W Hoover; Monita R Patel; Andrea Perez; Philip J Peters; Pam Pontones; Jeremy C Roseberry; Michelle Sandoval; Jessica Shields; Jennifer Walthall; Dorothy Waterhouse; Paul J Weidle; Hsiu Wu; Joan M Duwve
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-01       Impact factor: 17.586

View more
  4 in total

1.  Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014: Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus.

Authors:  Don C Des Jarlais; Kamyar Arasteh; Jonathan Feelemyer; Courtney McKnight; Susan Tross; David C Perlman; Aimee N C Campbell; Holly Hagan; Hannah L F Cooper
Journal:  Sex Transm Dis       Date:  2017-02       Impact factor: 2.830

2.  Behavioral, Psychological, Gender, and Health Service Correlates to Herpes Simplex Virus Type 2 Infection among Young Adult Mexican-American Women Living in a Disadvantaged Community.

Authors:  Kathryn M Nowotny; Jessica Frankeberger; Victoria E Rodriguez; Avelardo Valdez; Alice Cepeda
Journal:  Behav Med       Date:  2018-05-09       Impact factor: 3.104

Review 3.  Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned.

Authors:  April M Young; Abby E Rudolph; Jennifer R Havens
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

4.  Factors that influence enrollment in syringe services programs in rural areas: a qualitative study among program clients in Appalachian Kentucky.

Authors:  Umedjon Ibragimov; Katherine E Cooper; Evan Batty; April M Ballard; Monica Fadanelli; Skylar B Gross; Emma M Klein; Scott Lockard; April M Young; Hannah L F Cooper
Journal:  Harm Reduct J       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.